linjc16/ctgov huggingface dataset:
The Frequency of Thyroid Diseases in Women With Breast Cancer

Study Overview
=================
Brief Summary
-----------------
Breast cancer and thyroid disorders are important health challenges commonly encountered in women. The relationship between both conditions still remains unknown. In this study, the frequency of thyroid diseases was investigated in breast cancer patients

Official Title
-----------------
The Frequency of Thyroid Diseases in Women With Breast Cancer

Conditions
-----------------
Breast Cancer, Thyroid Diseases

Intervention / Treatment
-----------------
* Device: thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women, the age between 18-65 years who were diagnosed with breast cancer, but not underwent surgery, radiotherapy or chemothreapy were included into the study Exclusion Criteria: Those with pregnancy, known liver and renal failure, the history of any malignancy other than breast cancer, undergoing a surgical operation due to breast cancer, also those receiving chemotherapy/radiotherapy for the same reason or undergoing partial or complete thyroid surgery or a surgical operation within the past 6 months, and also the patients taking oral anti-diabetic medication, insulin, steroids, thiazide, anti-psychotics and immuno-suppressive medicines affecting the levels of blood glucose, insulin and IR, smokers and those consuming alcohol were excluded

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with breast cancer<br>Patients with breast cancer | Device: thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies<br>* thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies<br>|
| Control<br>Healthy patients without breast cancer | Device: thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies<br>* thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to investigate the frequency of thyroid diseases in breast cancer patients. |  | 1 year |
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

Study Overview
=================
Brief Summary
-----------------
To evaluate the antiviral activity and safety of two formulations of saquinavir in combination with licensed nucleoside antiretroviral drugs.

Detailed Description
-----------------
Patients are randomized to receive either hard gel or soft gel capsules of saquinavir in combination with at least one licensed nucleoside antiretroviral. Treatment will continue for 48 weeks. After the first 16 weeks, patients will be given the opportunity to roll over to the saquinavir formulation of choice.

Official Title
-----------------
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Saquinavir
* Drug: Lamivudine
* Drug: Stavudine
* Drug: Zidovudine
* Drug: Zalcitabine
* Drug: Didanosine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: HIV infection. Antiretroviral naiveness (i.e., less than 4 weeks of prior treatment) to at least one of the licensed nucleoside drugs. No more than 2 weeks of prior treatment with a protease inhibitor. No active opportunistic infection or other serious AIDS-defining condition. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Malabsorption or inadequate oral intake. Lab or clinical abnormality worse than grade 3 (other than exercise-induced CPK elevations). Unexplained, chronic diarrhea, defined as more than three loose stools per day persisting for 2 weeks or more within the month prior to study entry. Active malignancy or anticipated need for chemotherapy during the study. Anticipated need for disallowed medications during the study. Concurrent Medication: Excluded: Other protease inhibitors. Prior Medication: Excluded: More than 4 weeks of the prior nucleoside antiretroviral selected for the patient's regimen. More than 2 weeks of any protease inhibitor.

Ages Eligible for Study
-----------------
Minimum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Saquinavir|nan|
|Drug: Lamivudine|nan|
|Drug: Stavudine|nan|
|Drug: Zidovudine|nan|
|Drug: Zalcitabine|nan|
|Drug: Didanosine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Antiviral Agents, Saquinavir
Evaluating Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis

Study Overview
=================
Brief Summary
-----------------
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package- the Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel). Systemic sclerosis patients often develop pulmonary vascular disease leading to pulmonary hypertension. The TPD system may provide important insight into pulmonary blood vessels characteristics by the LDS (Lung Doppler Signals) signals that are related to pulmonary hypertension. The TPD performance in detecting PAH in SSc patients will be assessed in the study.

Official Title
-----------------
Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (SSc)

Conditions
-----------------
Systemic Sclerosis, Pulmonary Hypertension

Intervention / Treatment
-----------------
* Radiation: Ultrasound radiation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able and willing to give signed informed consent prior to enrollment Male or female, ≥ 18 years of age Diagnosis of SSc according to 2013 ACR/EULAR SSc Classification Criteria (van den Hoogen 2013): Score ≥ 9. Patients with RHC data available from measurement within 3 weeks prior to TPD assessment No change in or initiation of PAH specific therapy between the last RHC and TPD Exclusion Criteria: People unable or unwilling to give informed consent. PCWP or LVEDP > 15 mmHg Any PH etiology outside Group 1 (Dana Point, 2008) Pregnant women Patients having severe chest wall deformity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: Ultrasound radiation|Recording Doppler ultrasound noninvasively from the right chest wall|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1. Number of SSc patients correctly identified with pulmonary hypertension severity in each of the 4 defined groups by RHC. | Analyze Doppler data of 4 SSc groups (according to pulmonary hypertension severity) resulting in typical features. The features will be implemented in a pre-determined diagnostic algorithm that will determine the overall statistical success of the method in comparison to RHC data. | 12 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Systemic Sclerosis, Pulmonary hypertension, Lung Doppler Signals
A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to evaluate whether exposure to ice chips in the mouth (oral ice chips) during oxaliplatin treatment prevents or reduces symptoms of cold sensitivity.

Official Title
-----------------
A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity

Conditions
-----------------
GI Patients on Oxaliplatin Containing Regimen

Intervention / Treatment
-----------------
* Drug: Oxaliplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals ≥18 years of age will be enrolled. Patients must have histologic confirmation of a solid tumor malignancy that will be treated with a regimen that contains full-dose oxaliplatin. Patients may be receiving treatment in the neoadjuvant, adjuvant or metastatic setting. Patients must be treatment-naïve to platinum-agents at the time of enrollment. Prior treatment with non-platinum agents is permitted. Exclusion Criteria: Any active intraoral infection, including yeast infection (thrush) or active oral herpes simplex virus at the time of enrollment. Patients may not have dentures. Patients may not have a disorder that may result in altered taste sensation at baseline. This includes but is not limited to: persistent dry mouth.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm A<br>will be treated with consistent exposure to oral ice | Drug: Oxaliplatin<br>* Infusion<br>|
| Active Comparator: Arm B<br>Will not be treated with consistent exposure to oral ice. | Drug: Oxaliplatin<br>* Infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall intraoral cold sensitivity score | graded 0 to 4 | a minimum of four cycles (2 months) and a maximum of 12 cycles (6 months) |
Capnography in Infants Ventilated With High Frequency Ventilation

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that dEtCO2 measured by the Microstream® technique via a double-lumen ETT in infants ventilated with HFV would be feasible and adequately represent the arterial CO2 (PaCO2).

Detailed Description
-----------------
All infants with double lumen ETT on HFV are eligible.

Official Title
-----------------
Capnography in Infants Ventilated With High Frequency Ventilation: Prospective, Observational, Multi-Center Study

Conditions
-----------------
Infants in NICU Ventilated With HFV

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All intubated infants with double lumen ETT ventilated with HFV Exclusion Criteria: Infants ventilated with single lumen ETT

Ages Eligible for Study
-----------------
Minimum Age: 1 Minute
Maximum Age: 2 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The investigators primary outcome measure will be to evaluate the accuracy and the correlation of Microstream® dEtCO2 with the gold standard of PaCO2. |  | A Year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HVF, Premature infants, ETCO2
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix

Study Overview
=================
Brief Summary
-----------------
The DUO study's main objective is to evaluate, in the real life, the prevalence of cardiovascular risk in patients with prostate cancer that hormone treatment of androgen suppression by Degarelix was introduced. This study will also assess, at the initiation of therapy, the prevalence of osteoporosis, metabolic comorbidities, depression, sexual and geriatric patients suffering from prostate cancer.

Official Title
-----------------
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Drug: Degarelix


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male aged 18 years or older Diagnosed with prostate cancer Patient having received an antagonist of GnRH Degarelix prescription. Agreeing to and capable of completing in French during the visits all questionnaires on the impact of their illness and treatment. Patients having received oral and written study information, agreeing to the use of his anonymized data, and having signed a written Informed Consent Form. Exclusion Criteria: Patient included in an interventional study assessing treatment for prostate cancer. Patient presenting hypersensitivity to Degarelix or one of its excipients. Patient treated by other hormonotherapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Degarelix<br> | Drug: Degarelix<br>* Injection<br>* Other names: Firmagon;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of cardiovascular comorbidity | Measured by a history of at least one cardiovascular illness (according to ICD-10) and/or at least three cardiovascular risk factors (as defined by Cancer Committee of the French Urology Association) | At inclusion |
3D Ultrasound - Based Hysteroscopy Versus Virtual Hysteroscopy

Study Overview
=================
Brief Summary
-----------------
To prove that the 3 dimensional sonohysterography is, at least, as effective as the diagnostic hysteroscopy in examining the uterine cavity.

Official Title
-----------------
Contribution of 3D Sonohysterography and Virtual Hysteroscopy in Exploration of the Uterine Cavity in Comparison to the Diagnostic Hysteroscopy.

Conditions
-----------------
Endometrial or Uterine Pathology

Intervention / Treatment
-----------------
* Device: Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Diagnostic hysteroscopy prescribed either for a case of infertility or in case of doubt of endometrial / uterine pathology suspected by ultrasound or hysterography. Exclusion Criteria: Current Pregnancy. Genital infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 3 dimensional sonohysterography<br>3 dimensional sonohysterography | Device: Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)<br> <br> |
| Active Comparator: Standard hysteroscopy<br>Standard hysteroscopy | Device: Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Polyps, fibrosis, atrophy, hypertrophy and other uterine pathology detected by 3D sonohysterography (Accuracy of uterine cavity exploration by 3D sonohysterography) |  | 7 months |
Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations

Study Overview
=================
Brief Summary
-----------------
The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation. The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke. The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.

Official Title
-----------------
Biology of Cerebral Arteriovenous Malformations : Study of the Link Between Blood Biomarkers and the Haemorrhagic Prognosis of Cerebral Arteriovenous Malformations

Conditions
-----------------
Cerebral Arteriovenous Malformations, Ruptured or Unruptured Cerebral Arteriovenous Malformations

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient over 18 years old Patient with a cerebral AVM for which an intervention (endovascular treatment or surgery) or only clinical monitoring Express consent to participate in the study And children Free informed and express consent of both holders of the minor patient's parental authority, or, by way of derogation and only if the other holder of parental authority cannot give his or her consent within a time limit compatible with the methodological requirements specific to the conduct of the research with regard to its purposes, of one of the two holders of parental authority Exclusion Criteria: Patient benefiting from a legal protection measure Pregnant or breast feeding woman

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic | associaton between dosage of endothelial marker in blood samples and correlation with clinical outcome | 6 months | 
| Associaton between dosage of platelet and the arteriovenous malformation pronostic | Dosage of platelet in blood samples and correlation with clinical outcome | 6 months | 
| Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic | Dosage of neutrophilic in blood samples and correlation with clinical outcome | 6 months | 
| Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic | Dosage neo-angiogenesis activation markers in blood samples and correlation with clinical outcome | 6 months |
Observational Prospectif Monocentric Registry of Patients Suffering From VIE

Study Overview
=================
Brief Summary
-----------------
Patients with an episode of VTE (DVT and / or PE) have a mortality rate of 16-21% at 1 year after diagnosis. Morbidity associated with VTE is marked by the risk of recurrence, estimated at 30% and estimated at 29% after 8 years of follow post-thrombotic syndrome. For a number of these patients, risk factors have been identified (congenital or acquired thrombophilia, cancer, postpartum, surgery, prolonged immobilization, etc..). In 25-50% of cases, the etiology remains unknown, justifying the need for well-conducted studies to determine other potential risk factors. In addition, the expansion of treatment options with the arrival on the market of new direct oral anticoagulants, allows comparative studies on the effectiveness and frequency of adverse events for each treatment.

Official Title
-----------------
Observational Prospectif Monocentric Registry of Patients Suffering From VIE

Conditions
-----------------
Venous Thromboembolic Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of venous thromboembolism established by a validated test (venous Doppler ultrasound of the lower limbs, pulmonary angiography, lung scan ventilation / perfusion), diagnosis of venous thromboembolism made within 15 days, the previous inclusion in the register (outpatient or inpatient) Exclusion Criteria: person doesn't wish to participate in this study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of recurrent thromboembolic |  | at 1 year post-diagnosis | 
| bleeding complications incidence |  | at 1 year post-diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Venous, Thromboembolic, Pulmonary embolism